Diagnostic value of certain pro-inflammatory markers of coronavirus infection depending on the nature of the lung tissue damage

  • Received 17.03.2022

  • Revised 10.05.2022

  • Accepted 31.05.2022



  • 1,207 Views

  • Retrieved from Volume 4, No. 2, 2022

  • Pages 35-38

Summary. Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has caused a global health problem. COVID -19 often provokes an inadequate and excessive immune response, leading to the development of a "cytokine storm". The aim of the study – to investigate the level of IL-6 and LTB4 in patients with coronavirus infection depending on the nature of lung tissue damage. Materials and Methods. 49 people with COVID-19 aged (60.0±8.8) years, who were treated at Lviv Emergency Hospital were examined. Patients were divided into 2 groups: group 1 – patients with COVID-19 and interstitial lower lobe pneumonia; group 2 – persons with COVID-19 and interstitial polysegmental pneumonia. In all patients, the concomitant pathology was hypertension, and overweight or obesity. All individuals underwent blood test, biochemical blood test, which included glucose, alanine aminotransferase (ALT), aspartate aminotransferase (ACT), creatinine (with calculating glomerular filtration rate (GFR) according to the formula 2021 CKD-EPI Creatinine), urea, ferritin, C – reactive protein (CRP), and fibrinogen. LTB4 and serum IL-6 were determined by ELISA method. Results. Twenty-five patients with COVID-19 and lower lobe pneumonia aged (59.0±9.0) years were included in group 1; while group 2 included 24 individuals with COVID-19 and polysegmental pneumonia aged (58.4±8.8) years. Elevated levels of ESR, glucose, fibrinogen, CRP, ferritin, and LTB4 (p <0.01) were observed in patients of the two groups. Elevated levels of inflammatory mediators, namely LTB4 and IL-6, are likely to indicate the development of a cytokine storm in individuals with group 2 with polysegmental pneumonia in COVID-19. Conclusions. Patients with polysegmental coronavirus pneumonia have significantly higher LTB4 levels than those with COVID-19 and lower lobe pneumonia. Further study of pro-inflammatory mediators will improve the treatment strategy of this pathology, particularly in persons with comorbid pathology and risk factors for a more severe course of COVID-19

coronavirus disease, COVID-19, IL-6

https://doi.org/10.11603/bmbr.2706-6290.2022.2.13065

[1] Potere N, Batticciotto A, Vecchié A, Porreca E, Cappelli A, Abbate A, et al. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol [Internet]. 2021 [cited 2022 Apr 11];17(6): 601-18. Available from: https://pubmed.ncbi.nlm.nih.gov/33874829/https://pubmed.ncbi.nlm.nih.gov/33874829/.

[2] Liu F, Li L, Xu M Da, Wu J, Luo D, Zhu YS, et al. Prognostic  value  of interleukin-6,  C-reactive  protein, and  procalcitonin  in  patients  with  COVID-19.  J  Clin  Virol [Internet].  2020  Jun  1  [cited  2022 Apr  11];127. Available from: https://pubmed.ncbi.nlm.nih.gov/32344321/.

[3] Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A  systematic  review  and  meta-analysis.  Rev  Med  Virol [Internet].  2020  Nov  1  [cited  2022  Mar  30];30(6):1–9. Available from: https://pubmed.ncbi.nlm.nih.gov/32845568/.

[4] Santa Cruz A, Mendes-Frias A, Oliveira AI, Dias L, Matos AR, Carvalho A, et al. Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome Coronavirus 2 pneumonia. Front Immunol [Internet]. 2021 Feb  18  [cited  2022  Mar 31];12:613422. Available  from:  /pmc/articles/PMC7930905/.

[5] Citron F, Perelli L, Deem AK, Genovese G, Viale A. Leukotrienes, a potential target for Covid-19. Prostaglandins Leukot  Essent  Fatty  Acids  [Internet].  2020  Oct  1  [cited 2022 Apr  13];161:  102174. Available  from:  /pmc/articles/PMC7495247/.

[6] Al-kuraishy HM, Al-Gareeb AI, Almulaiky YQ, Cruz-Martins N, El-Saber Batiha G. Role of leukotriene pathway and  montelukast  in  pulmonary  and  extrapulmonary manifestations   of   Covid-19:   The   enigmatic   entity. Eur  J  Pharmacol  [Internet].  2021  Aug  5  [cited  2022 Apr   13];904:174196.   Available   from:   /pmc/articles/PMC8123523/.

[7] Afonso  P  V.,  Parent  CA.  Le leucotriène  B4  -  Un lipide  au  cœur  de  l’inflammation.  médecine/sciences [Internet].  2013  Dec  1  [cited  2022 Apr  27];29(12):  1083-5.  Available  from: https://www.medecinesciences.org/articles/medsci/full_html/2013/12/medsci20132912p1083/medsci20132912p1083.html.

[8] Archambault AS,  Zaid Y,  Rakotoarivelo  V, Turcotte C, Doré É, Dubuc I, et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. FASEB J [Internet]. 2021 Jun 1 [cited 2022 Apr 13];35(6): e21666. Available  from:  https://onlinelibrary.wiley.com/doi/full/10.1096/fj.202100540R. Eur  J  Pharmacol  [Internet].  2021  Aug  5  [cited  2022 Apr   13];904:174196.   Available   from:   /pmc/articles/PMC8123523/.7.  Afonso  P  V.,  Parent  CA.  Le  leucotriène  B4  -  Un lipide  au  cœur  de  l’inflammation.  médecine/sciences [Internet].  2013  Dec  1  [cited  2022 Apr  27];29(12):  1083-5.  Available  from:  https://www.medecinesciences.org/articles/medsci/full_html/2013/12/medsci20132912p1083/medsci20132912p1083.html.8. Archambault AS,  Zaid Y,  Rakotoarivelo  V, Turcotte C, Doré É, Dubuc I, et al. High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. FASEB J [Internet]. 2021 Jun 1 [cited 2022 Apr 13];35(6): e21666. Available  from:  https://onlinelibrary.wiley.com/doi/full/10.1096/fj.202100540R.